Regenerative medicine company Orthocell Limited announced its flagship nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving the recovery of erectile function and urinary continence post-surgery.

Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available.  The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market.

Orthocell CEO and MD, Paul Anderson, said: "The use of Remplir™ in nerve-sparing robotic-assisted radical prostatectomy highlights the product's versatility and superior performance in the protection and reconstruction of damaged peripheral nerves.

"Surgeons across multiple specialities—including orthopaedics, plastic and reconstructive surgery, and now urology—are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery.

"This represents a significant step forward in Remplir's organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device's global total addressable market."